🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia

RecruitingNAAges 18 Years - anyAllStanford University
NCT06283745 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients \>= 18 years of age * Patients who have qualitative olfactory distortion * Etiology of qualitative olfactory distortion is due to upper respiratory infection * Quantitative score under the 10th percentile on the SSParoT (HedRang and HedDir) * Quantitative score ≥ 8 on the QOD. * At least 6 months of parosmia but less than 24 months * Patients can have been previously treated with oral and topical steroids but this is not a requirement * Patients will receive concurrent olfactory training - the practice of smelling strong odors (standard of care) * Be able to read and understand English * Be able and willing to provide Informed Consent Exclusion Criteria: * Patients \< 18 years of age, pregnant females, patients who have structural abnormalities on nasal endoscopy or radiographic imaging that would prevent injection into the olfactory cleft * Olfactory loss due to trauma, chronic sinusitis / inflammation / polyps, neoplasms, or neurodegenerative diseases or patients who have had olfactory loss \> 24 months * Patients with bleeding disorders or on blood thinners such as coumadin and plavix
💊

What it tests

  • Platelet-rich Plasma (PRP)
  • Saline
📍

Where

1 site
Stanford Sinus Center / Stanford University School of Medicine
Palo Alto, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy